Mexico's Federal Commission for the Protection against Sanitary Risks (COFEPRIS) has published the new Official Mexican Standard NOM-137-SSA1-2025, which comprehensively modernizes the labeling requirements for all medical devices marketed in the country. This regulation replaces the previous 2008 version, introducing significant changes to align with international practices and new technologies.

Key updates include the introduction of electronic labeling, allowing health-related information to be supplemented through digital means such as QR codes, RFID, or websites. The standard establishes, for the first time, specific requirements for Software as a Medical Device (SaMD) and details the obligations for in vitro diagnostic agents, including self-tests.

A key change is the incorporation of a normative appendix with over 70 standardized symbols to communicate critical information regarding safety, sterility, and storage conditions. Furthermore, it requires that labeling development be based on a risk management approach.

The standard, published on March 11, 2026, will enter into force 360 days later. Once effective, a 180-day grace period will be granted to deplete existing stock of products with the previous labeling. This update represents a fundamental step toward strengthening patient safety, improving traceability, and facilitating the correct use of medical devices in Mexico.

This is a high-impact regulatory development because it represents a complete modernization and replacement of a foundational 17-year-old standard, mandating substantial changes to the labeling, packaging, and accompanying information for every medical device sold in Mexico. The impact is considered high because the changes are not merely procedural but require physical product and packaging redesign, investment in new systems, and a fundamental shift in compliance strategy across the entire industry. It directly affects product design, manufacturing, and supply chain operations, imposing significant costs and operational adjustments.

Key reasons for high impact:

• Complete Replacement: It fully repeals and replaces the NOM-137-SSA1-2008, forcing the entire industry to re-evaluate and update all existing product labeling.
• Mandatory Physical Changes: It introduces a comprehensive set of over 70 standardized symbols (e.g., for sterility, storage, warnings) that must be incorporated into label designs, requiring widespread packaging and artwork updates.
• Introduction of New Concepts: It establishes formal requirements for new and complex areas like Software as a Medical Device (SaMD) and electronic labeling (e-labeling) via QR codes or websites, which were not addressed in the previous standard.
• New Compliance Philosophy: It mandates that labeling content must be developed and evaluated based on a risk management process, a significant procedural shift for many manufacturers.
• Broad Scope: The regulation applies to all categories of medical devices, from simple consumables like bandages to complex diagnostic equipment and software, impacting the entire market without exception.
• Supply Chain Disruption: It necessitates significant investment in redesign, new printing processes, inventory management to phase out old stock, and staff training for manufacturers, importers, and distributors.
• Strict Deadlines: The 360-day entry-into-force plus a 180-day grace period creates a firm deadline for a complex, industry-wide transition.
• Voids Existing Compliance: All labeling compliant with the 2008 standard will become non-compliant, requiring a complete overhaul rather than minor amendments.

Who?

• Medical Device Manufacturers (both domestic and international) exporting to Mexico.
• Importers and Distributors of medical devices in Mexico, who are responsible for ensuring compliance.
• Regulatory Affairs, Legal, and Compliance Departments within medical device companies.
• Packaging Design and Engineering Teams responsible for implementing the new labels and symbols.
• IT and Digital Strategy Departments tasked with implementing e-labeling solutions (websites, QR codes).
• Acondicionadores (entities performing repackaging or relabeling activities in Mexico).
• Healthcare Professionals (doctors, nurses, lab technicians) and Patients, who are the end-users of the information.
• COFEPRIS and other health authorities responsible for market surveillance, inspections, and enforcement.

Conclusion

The new NOM-137-SSA1-2025 is a landmark regulatory overhaul for Mexico's medical device sector. By mandating a risk-based approach, standardized symbols, and rules for digital technologies like SaMD and e-labeling, it aims to significantly enhance patient safety and align Mexico with global best practices. While the transition poses substantial operational and financial challenges for the industry due to its high impact on product design and supply chain management, it ultimately sets a higher standard for clarity, safety, and traceability. Successful implementation will require proactive planning and investment from all stakeholders to navigate the transition and meet the 2027 compliance deadline.